Here we demonstrate that c-Cbl alters the tumor microenvironment and suppresses Programmed cell death-1 (PD-1) protein, an immune checkpoint receptor. Using syngeneic CRC xenografts, we observed significantly higher growth of xenografts and infiltrating immune cells in c-Cbl +/− compared to c-Cbl +/+ mice. Tumor-associated CD8+ T-lymphocytes and macrophages of c-cbl +/− mice showed 2-3-fold higher levels of PD-1. Functionally, macrophages from c-Cbl +/− mice showed a 4-5-fold reduction in tumor phagocytosis, which was restored with an anti-PD-1 neutralizing antibody suggesting regulation of PD-1 by c-Cbl. Further mechanistic probing revealed that C-terminus of c-Cbl interacted with the cytoplasmic tail of PD-1. c-Cbl destabilized PD-1 through ubiquitinationproteasomal degradation depending on c-Cbl's RING finger function. This data demonstrates c-Cbl as an E3 ligase of PD-1 and a regulator of tumor microenvironment, both of which were unrecognized components of its tumor suppressive activity. Advancing immune checkpoint and c-Cbl biology, our study prompts for probing of PD-1 regulation by c-Cbl in conditions driven by immune checkpoint abnormalities such as cancers and autoimmune diseases.
Results
The status of c-Cbl kockout in mice was confirmed by genotyping ( Supplementary Fig. 1A ) 5 . Given high expression of c-Cbl in immune cells, spleen was examined for CBL mRNA and c-Cbl protein. Extracts from spleen showed a significant reduction in CBL mRNA and c-Cbl protein levels corresponding to the status of CBL gene ( Supplementary Fig. 1A ). Next, we examined effects of c-Cbl reduction on tumor microenvironment using a syngeneic xenograft model; MC38 colon adenocarcinoma derived from C57BL/6 mice (a background similar to that of c-Cbl +/− mice). Compared to the c-Cbl +/+ mice (750 + 141.14 mm 3 ), MC38 xenografts in c-Cbl +/− mice showed a higher growth of the tumor and had double volume (average + SD 1290 + 251.9 mm 3 , p = 0.003) by the end of 4 weeks ( Fig. 1A-D ). c-Cbl −/− showed an even faster growth of xenograft. Within 12 days of post-injection, MC38 xenografts of c-Cbl −/− mice reached a significantly higher volume (3052 + 209.5 mm 3 , p < 0.001) compared to other groups (c-Cbl +/+ : 156 + 10 mm 3 and c-Cbl +/− : 202 + 35 mm 3 ) ( Fig. 1A) . Xenografts of c-Cbl −/− mice showed extensive skin ulceration warranting early euthanasia ( Fig. 1B-D) . Histopathology examination of xenografts of c-Cbl +/− and c-Cbl +/+ mice showed tumor cells. However, the xenograft from c-Cbl −/− mice revealed areas of severe necrosis and hemorrhage interspersed amidst the tumor cells ( Fig. 1E ). Since these changes in the xenografts will alter the microenvironment, subsequent studies were conducted in c-Cbl +/+ and c-Cbl +/− mice.
To further evaluate the tumor microenvironment, the xenografts were probed using a CD45+ antibody, a maker present on all leucocytes. Xenografts of MC38 from c-Cbl +/− mice showed more CD45+ infiltrates in comparison to c-Cbl +/+ mice ( Fig. 2A ), which was quantitated as the intensity density, a composite of pixel intensity and number, normalized to the tumor area. The tumor sections from c-Cbl +/− mice showed a significantly higher intensity density (0.73 + 0.34 intensity density/micron 2 ) compared to c-Cbl +/+ mice (0.02 + 0.01 intensity density/micron 2 , p = 0.043) (Fig. 2B ). These immune infiltrates consisted of both CD3+ lymphocytes and monocyte/macrophage lineage CD163+ cells ( Fig. 2C-F) . The quantification of both these immune infiltrates revealed a higher number of lymphocytes and a significantly higher number of macrophages in xenografts from c-Cbl +/− mice. These data suggested that the haploinsufficiency of c-Cbl increased tumor growth and immune infiltrates in the xenografts. c-Cbl is highly expressed in myeloid cells 4 and is involved in macrophage phagocytosis 15 . Upon infiltration in tumors, BMDM are known to phagocytose the tumor cells thereby assisting in regulating tumor growth 14, 16 . Based on this previous work, we anticipated that the increased macrophage infiltrates in c-Cbl +/− xenografts are likely to result in a lower tumor growth. Interestingly, our results were contrary to this expectation ( Fig. 1D,H) . We therefore posited that if c-Cbl +/− macrophages have reduced ability to phagocytose tumor cells. This contention was examined in BMDMs co-cultured with GFP-labeled tumor cells. Percentage of GFP+ macrophages served as a readout of tumor phagocytosis. Phagocytosis performed at 4 °C served as controls. Tumor cell phagocytosis by c-Cbl +/− macrophages was lower (6.5 + 1.59%) compared to that of c-Cbl +/+ macrophages (20.13 + 3.41%, p = 0.03) (Supplementary Fig. 2A,B ). Tumor phagocytosis at 4 0 c was the lowest. These data suggested that reduction in c-Cbl activity compromised the ability of macrophages to phagocytose tumor cells.
Recent studies have shown that macrophages perform tumor phagocytosis in a PD-1 dependent manner 14, 17, 18 . In these studies, treatment with pre-validated anti-PD-1 neutralizing antibody strikingly increased tumor phagocytosis by macrophages. In light of these findings, we examined tumor phagocytosis by Cbl +/− macrophages pre-treated with anti-PD-1 neutralizing antibody followed by exposure to GFP+ MC38 tumor cells ( Fig. 3A ). Using isotype antibody (serving as a control) and GFP+ MC38 tumor lines, at 37 °C, the Cbl +/− macrophages showed a significant reduction in phagocytosis (7.63 + 0.14%) compared to Cbl +/+ macrophages (12.95 + 1.68%, p = 0.013) ( Fig. 3B ).
Treatment of Cbl +/+ macrophages with anti-PD-1 neutralizing antibody prior to phagocytosis of GFP+ MC38 cells increased the % of GFP+ macrophages from 12.95 + 1.68% (control antibody) to 22.05 + 1.68% (p = 0.002), which corresponds to approximately 76% increase in phagocytosis ( Fig. 3A,B ). While a similar treatment of Cbl +/− macrophages increased tumor phagocytosis by 2.3-fold (control antibody 7.63 + 0.14%, anti-PD-1 neutralizing antibody 18.35 + 2.15%, p = 0.05). In fact, it restored tumor phagocytosis to a level similar to Cbl +/+ macrophages (p = 0.158). The above results were further supported by an orthogonal assay to detect macrophage phagocytosis. BMDM from c-Cbl +/+ and c-Cbl +/− mice pre-treated with anti PD-1 neutralizing antibody or isotype control were co-cultured with GFP+ MC38 cells and subjected to confocal microscopy. BMDMs were stained with PD-1 antibody and phagocytosed MC38 cells were detected by intracellular GFP signal. The PD-1+ cells with GFP+ were counted and presented as the percentage of total PD-1+ cells. The GFP+ cells outside/adjacent to the macrophages were excluded from the analysis ( Supplementary Fig. 2C , right upper panel, marked with a white # symbol). PD-1 staining in macrophages was observed in the membrane and the cytosol as the cells were permeabilized. Our analysis revealed that 10.40% + 1.51% (mean + SD) of c-Cbl +/+ macrophages treated with control IgG were GFP+. This proportion increased to 15.6% + 4.03% with the anti-PD-1 neutralizing antibody (p = 0.027). The c-Cbl +/− macrophages had significantly lower GFP+ cells, 4.60% + 2.96% compared to c-Cbl +/+ macrophages ( # p = 0.004, Supplementary Fig. 2D ). Treatment with anti-PD-1 neutralizing antibody increased the number of GFP+ c-Cbl +/− macrophages by 4-fold (18.60% + 4.72%, p = 0.005). These results demonstrated that c-Cbl +/− macrophages had reduced ability for tumor phagocytosis, which was rescued with anti-PD-1 neutralizing antibody. Taken together, both the above-described assays suggested that c-Cbl regulates tumor cell phagocytosis in a PD-1 dependent manner.
These results raised a possibility of the alterations of PD-1 levels in Cbl +/− macrophages, which was further examined in both TAMs ( Fig. 3) and BMDMs ( Fig. 4 ). For TAMs, we used F4/80, a marker of activated macrophages. Analysis of PD-1+ TAMs in MC38 xenografts of c-Cbl +/− showed a higher number of F4/80+ PD-1+ cells (average + SD 37.3 + 9.2%) compared to c-Cbl +/+ xenografts (21.2 + 4.55, p = 0.048) (Fig. 3C ). The mean fluorescence intensity (MFI) of PD-1 in TAMs of c-Cbl +/− mice was 2889 + 285 compared to 1911 + 315 in c-Cbl +/+ mice (p = 0.043) ( Fig. 3D ). Similarly, CD8+ T-lymphocytes from c-Cbl +/− mice xenografts showed close to a 4-fold increase in the MFI of PD-1 (average + SD 19308 + 3594) compared to c-Cbl +/+ mice (5195 + 1668, p = 0.007) and higher % of PD-1+ CD8+ T-lymphocytes in c-Cbl +/− mice (76.05 + 8.12%) compared to c-Cbl +/+ mice (41.03 + 12.89%, p = 0.052) ( Fig. 3C ). No changes in MFI of PD-1 were noted in CD4+ T-lymphocytes in www.nature.com/scientificreports www.nature.com/scientificreports/ tumors. Tumor-draining and other lymph nodes showed doubling of PD-1 expression on macrophages (c-Cbl +/− 3262 + 515 v/s c-Cbl +/+ 1646 + 218, p = 0.020) ( Fig. 3E ). On the other hand, immune cells from the spleen of c-Cbl +/− and c-Cbl +/+ mice showed no differences in macrophages and on CD8+ T-lymphocytes PD-1 MFI (Fig. 3F ). However, PD-1 expression is known to be low in spleen macrophages 19 . Together, these results showed higher PD-1 levels in tumor-associated immune cells from c-Cbl +/− mice.
We next examined the expression of PD-1 in macrophages from mice at baseline (not injected with tumors). Fluorescence activated cell sorting (FACS) analysis of BMDM from c-Cbl +/− mice showed more than two-fold greater percentage of PD-1+ macrophages (c-Cbl +/+ 8.91 + 2.75%, c-Cbl +/− 19.46 + 1.2%, p < 0.001) ( Fig. 4A,B ). BMDM were lyzed to examine the expression of c-Cbl and PD-1 in whole cell lysates. Compared to c-Cbl +/+ macrophages, c-Cbl +/− macrophages had 55% reduction in c-Cbl expression ( Supplementary Fig. 2E ) and a significant (65-80%) increase in PD-1 expression ( Fig. 4C ). PD-1 expression was further augmented with LPS. Collectively, the above results suggested that Cbl +/− mice had higher surface PD-1 at baseline and in tumor associated macrophages and CD8+ lymphocytes.
The restoration of phagocytosis in c-Cbl +/− macrophages using anti-PD-1 neutralizing antibody can potentially be due to an effect on PDL-1, a ligand of PD-1 receptor. A previous study showed that c-Cbl regulated PDL-1 through STAT, ERK and AKT signaling in lung cancer cells 20 . TAMs are also known to express PDL-1 21 . Therefore, we examined if c-Cbl activity regulated PDL-1 expression on macrophages. Our FACS analysis showed no difference in the levels of PDL-1 in BMDM from c-Cbl +/− and c-Cbl +/+ mice (p = 0.04) ( Fig. 4D ,E).
All of the above data raised a possibility of regulation of PD-1 by c-Cbl. First, we examined their interaction using a reciprocal immunoprecipitation assay performed on extracts of HEK293T cells co-expressing Myc-tagged PD-1 and Flag-tagged c-Cbl followed by immunoprecipitation using Flag-tagged or Myc-tagged antibody. The immunoprecipitation of c-Cbl showed co-precipitation of PD-1 and vice versa (Fig. 5A ). This interaction was also observed in RAW264.7 macrophages where the endogenous c-Cbl interacted with the endogenous PD-1. Immunoprecipitation of PD-1 showed co-immunoprecipitation of c-Cbl in these cells (Fig. 5B ). Both these data supported an interaction between PD-1 and c-Cbl in different cell types. In addition to wild-type c-Cbl, we used 70Z-c-Cbl (a naturally-occurring mutant of c-Cbl) is known to bind to but fails to degrade other targets of c-Cbl; thus, serving as a dominant negative 8, 11 . 70Z-c-Cbl did show binding to PD-1. Given that PD-1 has a cytoplasmic tail ( Supplementary Fig. 3 ) and that c-Cbl is a cytoplasmic protein, we posited that their interaction occurs through the cytoplasmic tail of PD-1. This contention was examined using GST-pull down assays by treating purified recombinant GST-tagged cytoplasmic tail of PD-1 with lysates from RAW264.7 macrophages. The cytoplasmic tail of PD-1 interacted with c-Cbl (Fig. 5C ). Similarly, of recombinant GST C-and N-termini of c-Cbl 11 , interaction of PD-1 was observed specifically with the C-terminus of c-Cbl (Fig. 5D ). Next, we examined if these two proteins co-localized in BMDM from c-Cbl +/+ mice. Endogenous PD-1 and c-Cbl showed co-localization within the cytosol (Fig. 5E ). Taken together, these results support an interaction of the C-terminus of c-Cbl with the cytoplasmic tail of PD-1.
Based on the results of binding assays and that the knowledge that c-Cbl +/− macrophages had increased PD-1, we hypothesized that c-Cbl might suppress PD-1. Reduction in c-Cbl activity with 70Z-c-Cbl or c-Cbl silencing (to an extent similar to c-Cbl +/− immune cells in Fig. 1A ) in RAW264.7 significantly upregulated (2-3-fold) endogenous PD-1 (Fig. 6A,B ). This effect is demonstrated by the ability of 70Z to bind to but fail to suppress PD-1 (Fig. 5A) . Thus, counteracting the regulation of endogenous c-Cbl on PD-1 in macrophages. These data generated in unstimulated macrophages are also consistent with the elevation of PD-1 levels observed in BMDM from uninjected mice (Fig. 4A,C) .
We further examined if this increase in PD-1 in whole cell lysate corroborated with the increased surface expression of PD-1. FACS analysis of 70Z-c-Cbl expressing RAW264.7 cells showed doubling of MFI of PD-1 (mean + SEM 7567 + 1247) compared to control (3367 + 636, p = 0.033) (Fig. 6C) . Interestingly, this increase was not associated with an augmented percentage of PD-1+ macrophages (Control: 3.79 + 0.38%, 70Z-c-Cbl: 3.15 + 0.20%, p = 0.255) (Fig. 6D) . These results suggest that the surface expression of PD-1 was increased in cells transfected with 70Z-c-Cbl. LPS treatment increased both MFI of PD-1 (4-5-fold) and % of PD-1+ cells (7-8-fold). With LPS treatment, a significant increase in MFI of PD-1 was also noted in 70Z-c-Cbl compared to control cells (Control: 7567 + 1247, 70Z-c-Cbl 38433 + 2824, p = 0.001) and increase in % of PD-1+ cells (Control: 4.81 + 0.51%, 70Z-c-Cbl: 31.17 + 3.46%, p = 0.005).
A similar regulation of PD-1 was noted in other cell types. Co-expression of PD-1 and 70Z-c-Cbl in HEK-293T cells increased PD-1 by 3-fold ( Fig. 6E) . A rescue experiment was performed in c-Cbl silenced cells transiently co-expressing c-Cbl and PD-1. Expression of c-Cbl restored the suppression of PD-1 (Fig. 6F ).
While no increase in PDL-1 was observed in c-Cbl +/− BMDM (Fig. 4D,E) , the levels of PDL-2 were low in c-Cbl +/+ and c-Cbl +/− BMDMs. In order to examine the effect of c-Cbl on both the ligands of PD-1, we explored 70Z-expressing RAW264.7 cells. Control or 70Z expressing RAW264.7 cells with or without LPS showed no difference in PDL-1 ( Supplementary Fig. 3A ) or PDL-2 levels ( Supplementary Fig. 3B ). Taken together, these results suggested that c-Cbl regulates the surface expression of PD-1 but not of its ligands and that PD-1 increase was amplified with pro-inflammatory conditions. c-Cbl degrades (destabilizes) its target proteins, and this process is measured by half-life studies 11, 22 . We examined PD-1 protein half-life in RAW264.7 cells expressing 70Z-c-Cbl. Using Cycloheximide, a protein translational inhibitor, we observed half-life of 72 minutes of endogenous PD-1, which was significantly prolonged and maximum values. Student's t-test were performed. *p = 0.007, **p = 0.050. (E) MFI of PD-1 on cells from lymph nodes of tumor-injected six mice in each group is shown. Student's t-test were performed. * p = 0.002. (F) MFI of PD-1 from splenic cells from un-injected mice six mice per group. Error bars = SEM.
www.nature.com/scientificreports www.nature.com/scientificreports/ by 70Z-c-Cbl to 180 minutes (Fig. 7A,B) . Similar results were noted in HEK-293T cells silenced for c-Cbl, which showed a significant increase in the half-life of overexpressed PD-1 from 3.25 hours to 8 hours (p = 0.02) ( Fig. 7C,D) . c-Cbl targets proteins for proteasomal or lysosomal degradation 4, 11 . We examined both these types of degradation in macrophages using inhibitors. Treatment of RAW264.7 with MG132, a proteasome inhibitor increased PD-1 up to 3-fold within one hour (Fig. 7E ). This result corroborates with the half-life of PD-1 (~ 45 minutes) in macrophages (Fig. 7B) . No changes were noted with lysosomal inhibitor Bafilomycin A1 (Fig. 7F) .
Because c-Cbl is a E3 ubiquitin ligase, we examined the possibility that c-Cbl mediated the ubiquitination of PD-1. This was addressed using both 70Z-c-Cbl and silencing CBL and by treating cells with MG-132, a commonly employed agent to block the proteasomal degradation and to increase the ubiquitination signal. Treatment with MG132 showed higher molecular weight bands up to 250 KD of PD-1, suggesting polyubiquitination of PD-1 (Fig. 7G,H) . This signal was reduced by 72-80% (p = 0.008) with 70Z-c-Cbl. Upon probing with a ubiquitin antibody, PD-1 polyubiquitination appeared as a smear, which was also reduced by 90% with c-Cbl silencing (p < 0.001) (Fig. 7H) . These experiments suggest that c-Cbl destabilizes PD-1 and targets it for ubiquitination and proteasomal degradation.
We further probed if c-Cbl-mediated PD-1 suppression was dependent on c-Cbl's E3 ligase activity. A naturally-occurring oncogenic point mutant of c-Cbl c.1111 T > C (p.371Y > H) with compromised ubiquitin E3 ligase activity was used 12 . X-ray crystallography studies have shown that this alteration imparts an auto-inhibited conformation to c-Cbl suppressing its ubiquitin ligase activity 23 . Our results showed that unlike wild-type c-Cbl, the cells expressing c-Cbl Y371H or del371 failed to downregulate PD-1 (Fig. 7I) . Consistent with the binding and lack of activity of 70Z-c-Cbl on PD-1 (Fig. 6A,C) , these results underscore the need for an intact RING finger domain activity of c-Cbl to suppress PD-1. 
Discussion
This study advances our understanding on the role of c-Cbl in tumorigenesis on several fronts. Previous work has shown that c-Cbl exerts its tumor suppressive effect by downregulating oncoproteins such as Wnt/β-catenin as well as receptor-and non-receptor tyrosine kinases in cancer cells 4, 7, 9, 24 . c-Cbl has also been shown to impede tumor-associated angiogenesis 7, 8 . The current work adds a previously unrecognized immunologic component to the tumor suppressive effect of c-Cbl. c-Cbl binds to the intracytoplasmic tail of PD-1 and targets it for ubiquitination-proteasomal degradation in macrophages, resulting in downregulation of PD-1 and reduced surface expression leading to increased tumor phagocytosis and tumor suppression ( Fig. 8) . While c-Cbl is a well-established signaling molecule in the context of central tolerance in the thymus 5 , we demonstrate a role of c-Cbl in the periphery such as in TAMs, a cell type which is increasingly targeted for therapeutic manipulation 25 .
This study also provides new insights into biology of PD-1 and identifies c-Cbl as a novel ubiquitin E3 ligase of PD-1. The C-terminus of c-Cbl contains several domains including a proline-rich region, which is known to interact with SH3-containing proteins 4 . It also has three tyrosine residues, which upon phosphorylation binds to SH2 domain-containing signaling molecules 4 . Moreover, PD1 is known to be phosphorylated at the tyrosine site 13, 26 . The interaction of c-Cbl and PD-1 was observed using recombinant protein of C-terminus of PD1 generated in E. coli, which is likely not phosphorylated. These observations suggest that the c-Cbl-PD-1 interaction may not depend on the phosphorylation status of PD-1 and may point to the interaction of PD-1 on the proline rich region of c-Cbl.
A recent study demonstrated that PD-1 undergoes ubiquitination by an E3 ubiquitin FBXO38, a multiprotein complex belonging to the SKP1-CUL1-F-box protein (SCF) family of ligases 27 . In activated T-lymphocytes, surface PD-1 undergoes internalization, subsequent ubiquitination, and proteasome degradation by FBXO38. Having more than one E3 ubiquitin ligase is not surprising. Important signaling proteins are known to be targeted by a set of E3 ubiquitin ligases that differ in terms of their binding to the target protein and degrade the target in a cell-type specific manner or in the context of upstream signaling. For example, oncogene β-catenin can be ubiquitinated by various E3 ubiquitin ligases namely β-TrCP, Jade-1, Ozz, and c-Cbl. They have distinct roles in regulating different species of β-catenin in different subcellular compartments depending on the phosphorylation status of the N-terminus of β-catenin 11, 22, 28 . More studies are needed to compare the relative roles of these two E3 ubiquitin ligases of PD-1 in immune cells and whether their interaction or subsequent degradation of PD-1 differs based on PTMs of PD-1 or signaling events. It is interesting to note that CBL families of protein also regulates the PDL-1/PDL-2 in different cell types. For example, in wild-type EGFR lung cancer cell lines A549 and H460, both Cbl-b and c-Cbl inhibited PD-L1 by inactivating STAT, AKT, and ERK signaling 20 . Along with these previous studies, the current manuscript demonstrates a direct role of c-Cbl in PD-1 degradation and raises a possibility of CBL family of proteins in regulation of other immune checkpoints.
c-Cbl is likely to suppress PD-1 in different states of immune cells. For example, PD-1 expression is maintained at low levels in unstimulated macrophages and is induced in the immune cells of the inflammatory milieu and tumor microenvironment. It is conceivable that in unstimulated macrophages, c-Cbl binds to the cytosolic tail of PD-1 and maintains a low level of PD-1, which may represent a physiologic function of c-Cbl in PD-1 regulation. This possibility is supported by regulation of PD-1 by c-Cbl in unstimulated macrophages (Fig. 4A,C) . That the effect of c-Cbl on PD-1 is several folds increased following pro-inflammatory cytokine stimulation (Figs. 4C, 6C) supports the notion that c-Cbl downregulates PD-1 in the inflammatory milieu to possibly prevent its uncontrolled expression. More studies are needed to probe these possibilities and other questions such as c-Cbl's regulation of PD-1 in different subsets of macrophages. This work was focused on macrophages and was motivated by the expression of c-Cbl in myelomonocytic cell lines and its mutation patterns in humans 3, 4, 12 . However, c-Cbl is also expressed in T-lymphocytes, which are altered in the tumor infiltrates of c-Cbl +/− mice and may contribute to the augmented tumor growth in them (Figs. 2C,D and 3C,D). Further work is needed to probe the effects of c-Cbl perturbation in different cell-types such NK cells or T-lymphocytes using chimeric mice or conditional cell-type specific KO mice.
The membrane proteins undergo either lysosomal or proteasomal degradation and the lysosomes play critical role in endocytosis of integral membrane proteins. The fate of the protein to either type of degradation depends in part by the type of ubiquitination such as polyubiquitination and monoubiquitination and the nature of ubiquitination chain at specific lysines K48 v/s K63 on the ubiquitin moiety 29 . It is known that c-Cbl can target proteins to either types of degradation 30 . Using specific lysosomal inhibitors (Bafilomycin), our data showed that PD-1 is targeted for proteasomal but not the lysosomal degradation (Fig. 7E,F) . Future studies will probe the specific signals that target PD-1 to the proteasomal degradation and also clarify questions related to mechanisms of increased immune infiltration in tumors with the reduction in c-Cbl activity, as this can be potentially leveraged to augment the efficacy of anti-PD-PDL-1 therapies. Despite an unprecedented clinical success, not all CRC patients respond to anti-PD-1-PDL1 therapeutics underscoring a need for other therapeutic targets that perturb several aspects of tumorigenesis. c-Cbl represents such a target with multi-pronged effects on cancer cells, angiogenesis and now immune cells. The current work strongly advocates for further probing of the mechanisms of degradation of other immune checkpoint proteins and their therapeutic relevance; as well as for the investigation of a potentially broader role that c-Cbl may play in other conditions driven by immune checkpoint abnormalities such as autoimmune diseases and viral infections.
Myc-tagged PD-1 were immunoprecipitated using Myc antibody. Eluents were probed with anti-ubiquitin antibody. 5% of lysates were probed for c-Cbl. Representative immunoblots from three experiments are shown. (I) HEK293T co-expressing Myc-tagged PD-1 and HA-tagged c-Cbl or control (CTL) constructs were probed and normalized to actin. Equal amounts of lysates were probed for HA-tag. Representative immunoblots from three independent experiments. 2-way ANOVA with multiple comparison and Student's t-test were performed. Compared to CTL, *p = 0.02 for c-Cbl. 
